Gentamicin in the treatment of staphylococcal infections

The Journal of International Medical Research
W B Chambers, A U Pallagrosi

Abstract

The aminoglycoside antibiotic, gentamicin, was used to treat staphylococcal infections in eighty-six patients in an open multicentre trial. Most of the infections involved the skin and soft tissue and the lower respiratory tract. Staphylococcus aureus was the only organism isolated in seventy-four patients; mixed flora were found in twelve. Gentamicin was administered, intramuscularly or intravenously, for 7 to 12 days (mean, 10 days) in a mean dose of 3-27 mg/kg per day. Clinical and bacteriological assessment of results indicated a complete resolution of the infection in fifty-three patients (61-6%) and a marked, moderate, or slight improvement in an additional twenty-nine patients (33.7%). Thus, a total of eighty-two patients ((95.3%) showed cure or improvement while only four patients (4-6%) failed to do so. Staphylococci persisted in six patients. Superinfection also occurred in six patients, however, it was considered to be clinically significant in only four of them. Screening for eighth cranial nerve, renal, hepatic and haematological function, before, during, and after gentamicin treatment, revealed no adverse reactions in these patients.

References

Dec 1, 1975·Southern Medical Journal·L D Sabath
Dec 11, 1976·Lancet·G T WilliamsS Tabaqchali
Aug 1, 1977·Postgraduate Medicine·R E Dixon
Jan 1, 1977·Antimicrobial Agents and Chemotherapy·G W Jordan, P D Hoeprich
Apr 1, 1976·Antimicrobial Agents and Chemotherapy·J J RahalN H Moldover
May 1, 1977·The Journal of Antimicrobial Chemotherapy·T D WyattE McCormick
Jun 1, 1976·Antimicrobial Agents and Chemotherapy·L D SabathM Finland
Jul 10, 1976·The Medical Journal of Australia·A PercevalC V Wellington
Mar 1, 1975·The American Journal of the Medical Sciences·J KlasterskyD Daneau
Apr 1, 1969·The Journal of Infectious Diseases·K Shimizu
Apr 1, 1969·The Journal of Infectious Diseases·P Federspil

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.